摘要
间充质基质细胞 (MSCs) 是成人多能前体的不同子集,以其在再生医学中的潜在治疗特性而闻名,主要通过分泌各种生物活性分子的旁分泌效应维持。 MSC 分泌组包括范围广泛的可溶性蛋白质因子,由生长因子和细胞因子以及囊泡成分组成,它们转移蛋白质和调节宿主微环境的遗传物质。特别是,MSC 衍生的分泌组介导血管生成过程的不同步骤,在体外诱导内皮细胞功能并在体内促进血管生成。因此,MSCs 已被广泛探索为一种有前途的基于细胞的治疗方法,用于治疗由血管生成不足引起的疾病。对动物心肌梗塞、缺血性中风和严重肢体缺血的大量研究表明,人 MSCs 可以增强血管生成并加速组织再生。这项广泛的临床前工作鼓励研究这些非凡的细胞在人类临床环境中治疗这些疾病。本综述全面概述了 MSCs 的促血管生成潜力及其分泌组的旁分泌效应。此外,还将介绍生物工程策略,包括体外预处理和基因改造方法,以增强 MSC 先天性血管生成特性,从而增强治疗效力。最后,将讨论已完成的 MSCs 治疗缺血相关疾病的临床前和临床研究的最新情况。
关键词: 血管生成、间充质基质细胞、分泌组、离体预处理、基因工程、缺血性疾病。
图形摘要
Current Gene Therapy
Title:Mesenchymal Stromal Cells (MSCs): A Promising Tool for Cell-Based Angiogenic Therapy
Volume: 21 Issue: 5
关键词: 血管生成、间充质基质细胞、分泌组、离体预处理、基因工程、缺血性疾病。
摘要: The Mesenchymal stromal cells (MSCs) are a diverse subset of adult multipotent precursors, known for their potential therapeutic properties in regenerative medicine mainly sustained by paracrine effects through secretion of a variety of biologically active molecules. MSC secretome includes a wide range of soluble protein factors, composed of growth factors and cytokines, and vesicular components, which transfer proteins and genetic material modulating the host microenvironment. In particular, MSC-derived secretome mediates the different steps of the angiogenic process, inducing endothelial cell functions in vitro and promoting angiogenesis in vivo. As a result, MSCs have been widely explored as a promising cell-based therapy in diseases caused by insufficient angiogenesis. Numerous studies of myocardial infarction, ischemic stroke, and critical limb ischemia in animals have shown that human MSCs can enhance angiogenesis and accelerate tissue regeneration. This extensive preclinical work encouraged the study of these remarkable cells for the treatment of these disorders in human clinical settings. The present review provides a comprehensive overview of the pro-angiogenic potential of MSCs and paracrine effectors of their secretome. In addition, bioengineering strategies, including ex vivo preconditioning and genetic modification approaches, to enhance MSC innate angiogenic properties, and thereby therapeutic potency, will be presented. Finally, an update on completed preclinical and clinical studies with MSCs for the treatment of ischemia-related diseases will be discussed.
Export Options
About this article
Cite this article as:
Mesenchymal Stromal Cells (MSCs): A Promising Tool for Cell-Based Angiogenic Therapy, Current Gene Therapy 2021; 21 (5) . https://dx.doi.org/10.2174/1566523221666210917114353
DOI https://dx.doi.org/10.2174/1566523221666210917114353 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Radionuclide PET and PET/CT in Coronary Artery Disease
Current Pharmaceutical Design Cocaine Dependence and Stroke: Pathogenesis and Management
Current Neurovascular Research Treatment of Pulmonary Thromboembolism in Patients with Systemic Blood Pressure Stability and Right Ventricular Dysfunction
Current Respiratory Medicine Reviews New Molecular Targets of Anticancer Therapy – Current Status and Perspectives
Current Medicinal Chemistry Biomarkers in Unstable Carotid Plaque: Physiopathology and Prediction
Cardiovascular & Hematological Agents in Medicinal Chemistry Genetics of Hypertrophic and Dilated Cardiomyopathy
Current Pharmaceutical Biotechnology Pharmacological Inhibition of Poly(ADP-ribose) Polymerase in Cardiovascular Disorders: Future Directions
Current Vascular Pharmacology Editorial: [Hot Topic: Molecular Image-Guided Theranostics and Personalized Medicine]
Current Medical Imaging The Role of Toll-Like Receptors in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis: A New Promising Therapeutic Approach?
CNS & Neurological Disorders - Drug Targets Heart Disease Induced by AAS Abuse, Using Experimental Mice/Rats Models and the Role of Exercise-Induced Cardiotoxicity
Mini-Reviews in Medicinal Chemistry Metallothionein as a Scavenger of Free Radicals - New Cardioprotective Therapeutic Agent or Initiator of Tumor Chemoresistance?
Current Drug Targets Recent Advances in Hematopoietic Stem Cell-Mediated Regeneration
Recent Patents on Regenerative Medicine Drug Therapy in Brugada Syndrome
Current Drug Targets - Cardiovascular & Hematological Disorders The FDG-PET Revolution of Medical Imaging – Four Decades and Beyond
Current Molecular Imaging (Discontinued) Histamine as a Potential Adjuvant to Immuno and Radiotherapy for Cancer Treatment: Discovering New Functions for the Oldest Biogenic Amine
Current Immunology Reviews (Discontinued) Salvia miltiorrhiza: A Potential Red Light to the Development of Cardiovascular Diseases
Current Pharmaceutical Design New Ways of Detecting ADRs in Neonates and Children
Current Pharmaceutical Design Bone Loss and Osteoporosis are Associated with Conversion from Mild Cognitive Impairment to Alzheimer’s Disease
Current Alzheimer Research Pluronic-Based Core/Shell Nanoparticles for Drug Delivery and Diagnosis
Current Medicinal Chemistry Neuron Protection as a Therapeutic Target in Acute Ischemic Stroke
Current Topics in Medicinal Chemistry